Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (361-370 of 466) with videos related to

Pageof 47
Sort By:
Nature Communications|April 18, 2023
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Haematologica|March 15, 2015
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal studyAnders Österborg, Roxanne C Jewell, Swami Padmanabhan-Iyer, et al.
Blood|October 22, 2015
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialKirsten Fischer, Jasmin Bahlo, Anna Maria Fink, et al.
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
European Journal of Haematology|May 2, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registryNadine Kutsch, Adam Giza, Sandra Robrecht, et al.
Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.
Hemasphere|July 25, 2024
The role of trephine bone marrow biopsies in the era of measurable residual disease<b>-</b>Results from the CLL10 trial of the German CLL Study Group (GCLLSG)Nadine Kutsch, Sandra Robrecht, Anna Fink, et al.
Leukemia & Lymphoma|September 2, 2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemiaClemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, et al.
Nature Genetics|January 19, 2016
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaChristopher C Oakes, Marc Seifert, Yassen Assenov, et al.
Pageof 47

Showing results (361-370 of 466) with videos related to

Sort By:
Pageof 47
Nature Communications|April 18, 2023
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Haematologica|March 15, 2015
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal studyAnders Österborg, Roxanne C Jewell, Swami Padmanabhan-Iyer, et al.
Blood|October 22, 2015
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialKirsten Fischer, Jasmin Bahlo, Anna Maria Fink, et al.
Haematologica|August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisAxel Benner, Larry Mansouri, Davide Rossi, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
European Journal of Haematology|May 2, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registryNadine Kutsch, Adam Giza, Sandra Robrecht, et al.
Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.
Hemasphere|July 25, 2024
The role of trephine bone marrow biopsies in the era of measurable residual disease<b>-</b>Results from the CLL10 trial of the German CLL Study Group (GCLLSG)Nadine Kutsch, Sandra Robrecht, Anna Fink, et al.
Leukemia & Lymphoma|September 2, 2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemiaClemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, et al.
Nature Genetics|January 19, 2016
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaChristopher C Oakes, Marc Seifert, Yassen Assenov, et al.
Pageof 47